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Background
With the advent of direct-acting antivirals, the rate of sus-
tained virologic response (SVR) after treatment for chronic
HCV infection has dramatically increased [1]. However,
recent data show that there is cause for concern regarding
the potential emergence of viral resistance [2].
Methods
We performed a study to assess the antiviral resistance
profile in a series of patients with limited treatment
options for chronic HCV infection.
Results
We assessed data from 12 patients (gender ratio 1:1), of
which 10 had HCV monoinfection and 2 had HCV+HIV
coinfection. The mean age was 43.8 ± 16.5 years (range
19-71 years). Eleven patients were infected with HCV gen-
otype 1b, and one patient had been coinfected with geno-
type 2a/2c but had spontaneously cleared 2a infection and
was now monoinfected with HCV 2c.
Only one patient had IL28-B genotype CC, 4 patients
CT and 5 patients TT (in two cases data on IL28-B were
not available). Seven of the patients had received prior
anti-HCV therapy: 2 with peg-interferon+ribavirin, 2 with
faldaprevir-based regimens and 3 with telaprevir-based
regimens. Of them, 3 had been non-responders and 4 had
been relapsers.
The mean plasma HCV-RNA was 6.1±0.7 log10 IU/
mL. Patients were distributed over the whole range of
fibrosis values on FibroMax, with a slight predominance
of advanced fibrosis: F3 (2 patients) and F4 (3 patients).
Resistance to boceprevir or simeprevir was identified
in 3/12 cases (fold-change range: 4-24) and 2/12 cases
(fold-change range: 32-38), respectively, although none
of the patients had received prior therapy with these
antivirals.
Resistance to telaprevir was identified in 3/12 cases
(surprisingly, none of the cases with telaprevir therapy).
Possible resistance was identified in another 6 cases
(including cases treated with telaprevir and faldaprevir).
The overall fold-change range was 1.8-22.4.
Resistance to faldaprevir was identified in 3/12 cases
(surprisingly, none of the cases with faldaprevir therapy),
with a fold-change range of 1.2-360.0.
Conclusion
Cross-resistance to HCV protease inhibitors (PI)
remains a cause for concern, particularly in patients
with history of treatment with HCV PI-based regimens.
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